Cannabis Technologies Develops CTI-091, a Second Therapy
Cannabis Technologies Inc. (CSE:CAN,OTCQB:CANLF) announced that it has developed a therapy called CTI-091; it contains a proprietary mixture of cannabinoids and active ingredients not based on cannabis. Its purpose is to relieve “joint pain and swelling associated with arthritis and joint disease.”
As quoted in the press release:
Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression.
CTI-091 is designed to enhance retention and absorption of the key ingredients around the target site and designed for the relief of joint pain and swelling.
Currently the formulation is in preclinical stage of development. The company is also working to improve the delivery system to increase efficacy. We are expecting to go to initiate clinical phase 1 trials upon completion of these steps
Craig Schneider, president and CEO of Cannabis Technologies, commented:
We are extremely pleased to announce a second therapy in our expanding product pipeline. The pain and arthritis therapy takes our company to the next stage of development, reinforcing the proof of concept of our Cannabinoid Drug Design Platform. This platform is designed to effectively identify and fast track new drug therapies. The company plans to have numerous therapies over the next 12 months within the product pipeline focusing on other areas like metabolic diseases (Obesity & Diabetes), Orphan diseases (Huntington’s & Epilepsy) as well as Cancer and Angiogenesis.